glp‑1 therapy alcoholism

GLP-1 reduces heavy drinking days in treatment seeking people with alcohol use disorder and obesity, finds small trial — Phot

7 Patients Cut 38% Heavy Drinking With Obesity Treatment

GLP-1 therapy reduces heavy drinking days in obese patients by targeting appetite and reward pathways, cutting weekly binge episodes. In a 2024 pilot, eight weeks of treatment lowered heavy drinking by 38% without adding new medications. In a 2024 pilot trial, just 8 weeks of GLP-1 therapy cut heavy drinking